Heart failure is associated with an increased risk of cancer development and progression, potentially driven by shared risk factors and specific molecular pathways such as SerpinA3.
Heart failure is increasingly recognized as an independent risk factor for cancer development and progression, suggesting a bidirectional relationship in cardio-oncology.
PURPOSE OF REVIEW: The co-occurrence of heart failure (HF) and cancer represents a complex and multifaceted medical challenge. Patients with prevalent cardiovascular disease (CVD), particularly HF, exhibit an increased risk of cancer development, raising questions about the intricate interplay between these two prevalent conditions. This review aims to explore the evolving landscape of cancer development in patients with HF, shedding light on potential mechanisms, risk factors, and clinical implications. RECENT FINDINGS: Epidemiological data suggests higher cancer incidences and higher cancer mortality in HF patients, which are potentially more common in patients with HF with preserved ejection fraction due to related comorbidities. Moreover, recent preclinical data identified novel pathways and mediators including the protein SerpinA3 as potential drivers of cancer progression in HF patients, suggesting HF as an individual risk factor for cancer development. The review emphasizes preliminary evidence supporting cancer development in patients with HF, which offers several important clinical interventions such as cancer screening in HF patients, prevention addressing both HF and cancer, and molecular targets to treat cancer. However, there is need for more detailed understanding of molecular and cellular cross-talk between cancer and HF which can be derived from prospective assessments of cancer-related outcomes in CV trials and preclinical research of molecular mechanisms.
Seuthe et al. (Sat,) conducted a review in Heart failure and cancer. Heart failure is associated with an increased risk of cancer development and progression, potentially driven by shared risk factors and specific molecular pathways such as SerpinA3.